Izotropic (FRA:1R3) ROCE %: 0.00% (As of Jan. 2026)


FRA:1R3 Izotropic Corp FRA:1R3
28 GF Score
Price €0.14
! 2 Warning Signs
View Full Analysis

What is Izotropic ROCE %?

Izotropic FRA:1R3 28 ROCE % is 0.00% as of Jan. 2026. GuruFocus rates FRA:1R3 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Izotropic's annualized ROCE % for the quarter that ended in Jan. 2026 was 0.00%.

Izotropic  (FRA:1R3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Izotropic ROCE % Related Terms

Izotropic ROCE % Historical Data

* Premium members only.

The historical data trend for Izotropic's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Izotropic ROCE % Chart

Izotropic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROCE %
Get a 7-Day Free Trial Premium Member Only -191.05 -354.08 0.00 0.00 0.00

Izotropic Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1R3
28GF Score
Izotropic Corp FRA:1R3
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Izotropic ROCE % Calculation

Izotropic's annualized ROCE % for the fiscal year that ended in Apr. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-1.817/( ( (0.158 - 2.769) + (0.264 - 3.357) )/ 2 )
=-1.817/( (-2.611+-3.093)/ 2 )
=-1.817/-2.852
=63.71 %

Izotropic's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-0.492/( ( (0.275 - 3.652) + (0.423 - 3.684) )/ 2 )
=-0.492/( ( -3.377 + -3.261 )/ 2 )
=-0.492/-3.319
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Izotropic (FRA:1R3) has a ROCE % of 0.00% as of Jan. 2026.
Is Izotropic's ROCE % too high?
Izotropic's current ROCE % is 0.00%. Overall, Izotropic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Izotropic's ROCE % compare to TMO and DHR?
Izotropic's ROCE % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Izotropic's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Izotropic stock overvalued right now?
Izotropic (FRA:1R3) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Izotropic's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Izotropic (FRA:1R3), the current ROCE % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Izotropic Business Description

Address 800 - 15355 24th Avenue, Suite 424, Surrey, BC, CAN, V4A 2H9
Izotropic Corp is a research and development company specializing in cancer research and early detection for breast cancer. It is engaged in advancing breast cancer imaging through the commercialization of medical imaging technologies. The company's current focus is on the commercialization of its first medical imaging device, IzoView, a dedicated Breast CT Imaging System, developed to provide high resolution, true 3D volumetric visualization of the breast without compression for breast cancer detection and diagnosis.
28GF Score

Get the complete analysis for FRA:1R3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price